Synapse - Yelena Janjigian

Results (400)

Genomic landscape of late-stage gastric cancer: Analysis from KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 studies

Journal Article

Janjigian, Y. Y.; Cecchini, M.; Shitara, K.; Enzinger, P. C.; Wainberg, Z. A.; Chau, I.; Satoh, T.; Lee, J.; Nebozhyn, M.; Loboda, A.; more...
JCO Precision Oncology (2025)

Fulltext@MSK | Save

Landscape of subsequent therapies in perioperative immunotherapy trials across multiple cancer types

Journal Article

Semaan, K.; Nawfal, R.; Nally, E.; Janjigian, Y. Y.; Robert, C.; Peters, S.; Powles, T.; Choueiri, T. K.
Lancet Oncology (2025)

Fulltext@MSK | Save

A phase II study of agenT-797 (invariant natural killer T-cells), botensilimab (Fc-enhanced CTLA-4 inhibitor) and balstilimab (anti-PD-1) in patients with advanced, refractory gastroesophageal adenocarcinoma

Meeting Abstract

Cytryn, S. L.; Maron, S. B.; Janjigian, Y. Y.
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

CLARITY-Gastric 01: A randomized phase 3 study of AZD0901, a Claudin18.2 (CLDN18.2)-targeted antibody-drug conjugate, in second- or later-line (2L+) advanced gastric or gastroesophageal junction cancer (GC/GEJC)

Meeting Abstract

Janjigian, Y. Y.; Shitara, K.; Elimova, E.; Zhang, J.; Chen, M. H.; Smyth, E. C.; Lee, J.; Miao, R.; Liu, S.; Holmblad, M.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Valemetostat and trastuzumab deruxtecan (T-DXd) in previously treated advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastric cancer or gastro-esophageal junction (GEJ) adenocarcinoma

Meeting Abstract

Shitara, K.; Enzinger, P. C.; Mohapatra, A.; Janjigian, Y. Y.
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

KEYMAKER-U06: Phase 1/2 umbrella platform study of TROP2 antibody-drug conjugate sacituzumab tirumotecan plus pembrolizumab plus chemotherapy (substudy 06C) and sacituzumab tirumotecan plus paclitaxel (substudy 06D) in gastroesophageal adenocarcinoma

Meeting Abstract

Oh, D. Y.; Xu, J.; Tabernero, J.; Van Cutsem, E.; He, T.; Bhaumik, S.; Bhagia, P.; Janjigian, Y. Y.
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Updated results from the trastuzumab deruxtecan (T-DXd) 5.4 mg/kg triplet combination of DESTINY-Gastric03 (DG-03): First-line (1L) T-DXd with fluoropyrimidine (FP) and pembrolizumab in advanced/metastatic HER2-positive (HER2+) esophageal adenocarcinoma, gastric cancer (GC), or gastroesophageal junction adenocarcinoma (GEJA)

Meeting Abstract

Janjigian, Y. Y.; Van Laarhoven, H. W. M.; Rha, S. Y.; Kozlov, V.; Oh, D. Y.; Gravina, A.; Rapatoni, L.; Shoji, H.; Hofheinz, R. D.; Chen, L. T.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Association between adjuvant component of perioperative chemotherapy and survival outcomes in resected gastric cancer (GC)

Meeting Abstract

Sreeram, A.; Yeh, C.; Toumbacaris, N.; Capanu, M.; Shimada, S.; Gu, P.; Janjigian, Y. Y.; Ilson, D. H.; Strong, V. E.; Ku, G. Y.
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up results from CheckMate 649